Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type ii diabetes mellitus

Experimental and Therapeutic Medicine

Volumn 7, Issue 6, 2014, Pages 1752-1756

  Su, Yong ^a   Su, Ya Li ^a   Lv, Li Fang ^a   Wang, Li Min ^a   Li, Quan Zhong ^a   Zhao, Zhi Gang ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Blood lipid; Body weight; Hepatorenal function; Type ii diabetes mellitus; Vildagliptin; glucosidase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UREA; VILDAGLIPTIN;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEPATORENAL FUNCTION; HUMAN; HYPOGLYCEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REDUCTION; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 84898412435     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1637     Document Type: Article

References (21)

1. Samraj GP: Vildagliptin for the treatment of diabetes. Therapy 8: 703-719, 2011.
2. Croxtall JD and Keam SJ: Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 68: 2387-2409, 2008.
3. Masuda K, Aoki K and Terauchi Y: Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance. J Diabet Invest 2: 435-440, 2011.
4. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K and Terauchi Y: Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 49: 225-230, 2012.
5. Narita T, Katsuura Y, Sato T, et al: Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide response after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 26: 187-188, 2009.
6. Arakawa M, Ebato C, Mita T, et al: Miglitol suppresses the postprandial increases in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 57: 1299-1306, 2008.
7. Aoki K, Miyazaki T, Nagakura J, Orime K, Togashi Y and Terauchi Y: Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide levels in healthy men. Endocr J 57: 673-677, 2010.
8. Pi-Sunyer FX, Schweizer A, Mills D and Dejager S: Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 76: 132-138, 2007.
9. Tahrani AA, Piya MK and Barnett AH: Drug evaluation: vildagliptin-metformin single-tablet combination. Adv Ther 26: 138-154, 2009.
10. Ahrén B: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 23: 487-498, 2009.
11. Bosi E, Dotta F, Jia Y and Goodman M: Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 11: 506-515, 2009.
12. Devendra D, Gohel B, Bravis V, et al: Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 63: 1446-1450, 2009.
13. Matthews DR, Dejager S, Ahren B, et al: Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with gimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 12: 780-789, 2010.
14. Iwamoto Y, Kashiwagi A, Yamada N, et al: Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 12: 700-708, 2010.
15. Schweizer A, Dejager S, Foley JE, Shao Q and Kothny W: Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a data base of clinical trials. Diabetes Obes Metab 13: 55-64, 2011.
16. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A and Kothny W: An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 12: 495-509, 2010.
17. Richard KR, Shelburne JS and Kirk JK: Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 33: 1609-1629, 2011.
18. Kahn SE, Haffner SM, Heise MA, et al: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443, 2006.
19. Dormandy JA, Charbonnel B, Eckland DJ, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289, 2005.
20. Ilag LL, Kerr L, Malone JK and Tan MH: Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 29: 1254-1270, 2007.
21. Neumiller JJ: Differential chemistry (structure), mechanisnm faction, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitor. J Am Pharm Assoc (2003) 49 (Suppl 1): S16-S29, 2009.